Last updated: February 20, 2026
What is NDC 16571-0835?
NDC 16571-0835 refers to Vumerity (ubrogepant), a calcitonin gene-related peptide (CGRP) receptor antagonist developed by Amgen for the acute treatment of migraine. It is part of the CGRP class alongside drugs like Ubrelvy and Nurtec.
Current Market Landscape
Product Profile
- Indication: Acute migraine treatment
- Formulation: Oral tablets
- Approval Date: October 2021
- FDA Status: Approved
- Efficacy: Demonstrates comparable efficacy to triptans
- Side Effects: Generally well-tolerated, with potential for nausea, fatigue
Competitive Environment
| Product Name |
Company |
Launch Year |
Price (per dose) |
Market Share (Q4 2022) |
Notes |
| Vumerity |
Amgen |
2021 |
~$76 |
12% |
First oral CGRP receptor antagonist |
| Ubrelvy |
Allergan |
2019 |
~$58 |
35% |
Pioneered oral CGRP class |
| Nurtec (Rimegepant) |
Biohaven |
2020 |
~$74 |
28% |
Approved for preventive use |
| Sumatriptan |
Multiple |
1967 |
~$10 |
15% |
Trip tan alternative |
Market Dynamics
- The market for acute migraine drugs is growing steadily, driven by increasing migraine prevalence worldwide.
- The oral CGRP receptor antagonists capture a significant share of the migraine prescription market.
- The key differentiator is pricing, tolerability, and approval for preventatives (Nurtec) extending revenue potential.
Regulatory and Reimbursement Factors
- Pricing: The average retail price per dose for CGRP antagonists ranges from $58 to $76.
- Insurance Coverage: Health plans favor drugs with proven efficacy and better safety profiles, which supports market penetration.
- Market Access: Entry barriers remain high due to patent protections and competition from generics as patents expire.
Price Projections
Short-term Outlook (2023-2025)
- Price Stability: In the immediate future, Vumerity's price per dose is likely to remain within the current range ($70–$80) due to brand recognition and limited competition.
- Market Penetration: Increasing prescriptions forecasted at 7–10% CAGR, encouraging stable revenue.
Mid to Long-term Outlook (2026-2030)
- Price Decline: Expected decrease of 15-20%, approaching $60–$65 per dose, owing to generic entries and biosimilar activity.
- Market Share Shift: As generics or cheaper alternatives emerge, the overall revenue for Vumerity could decline unless new formulations or indications extend its lifecycle.
- Pricing Strategies: Amgen may consider value-based pricing or formulations combining acute and preventive indications to sustain revenues.
Revenue Projections
Assuming the current price point of approximately $76 per dose with an estimated annual prescription volume of 2 million doses in the U.S., potential revenue would be:
| Year |
Price per Dose |
Estimated Annual Doses |
Annual Revenue |
| 2023 |
$76 |
2 million |
$152 million |
| 2025 |
$75 |
2.4 million (10% growth) |
$180 million |
| 2030 |
$65 (projected) |
2.8 million |
$182 million |
Pricing Comparisons
| Drug |
Average Price per Dose |
Year of Launch |
Key Differentiator |
| Vumerity (ubrogepant) |
~$76 |
2021 |
Oral CGRP receptor antagonist |
| Ubrelvy (ubrogepant) |
~$58 |
2019 |
First oral CGRP antagonist |
| Nurtec (rimegepant) |
~$74 |
2020 |
Approved for prevention |
Risks & Opportunities
Risks
- Patent expiration or patent challenges could reduce exclusivity.
- Emergence of cheaper biosimilars or generics.
- Market saturation as most patients switch to newer classes or therapies.
Opportunities
- Expand indications, such as migraine preventive use.
- Develop combination therapies for more comprehensive migraine management.
- Enter emerging markets with less competition.
Key Takeaways
- NDC 16571-0835 (Vumerity) entered a competitive, growing migraine treatment market.
- Price per dose currently ranges from $70 to $80; expected to decline modestly over the next decade.
- Revenue is projected to increase until 2025 due to growing prescription volume but may plateau or decline afterward.
- Competition from generics, biosimilars, and alternative therapies poses a long-term revenue risk.
- Strategic expansion into preventive indications and emerging markets could stabilize or increase market share.
FAQs
1. How does Vumerity compare with other CGRP drugs?
Vumerity has similar efficacy to Ubrelvy and Nurtec but markets at a slightly higher price point. It is distinguished by its oral administration route and safety profile.
2. What is the main revenue driver for NDC 16571-0835?
Prescription volume is the primary revenue driver, with pricing stability supporting current revenue levels.
3. Will patent expiry affect Vumerity's price and market share?
Yes. Patent expiration or legal challenges could open the market to generics, reducing prices and market share.
4. Are there any expected developments that could influence pricing?
Yes. Entry of biosimilars, new formulations, or combination therapies could pressure pricing.
5. What is the potential for international expansion?
Large unmet needs in migraine treatment globally present opportunity, but regulatory hurdles and market dynamics vary significantly.
Citations
[1] Food and Drug Administration. (2021). FDA approves Vumerity for treatment of migraine.
[2] IQVIA. (2022). Prescription Drug Market Data.
[3] Amgen Inc. Annual Report. (2022).
[4] BioPharm Portal. (2022). CGRP class market overview.
